JAMA publications are gearing up for a 2013 rebrand

Share this article:
Howard Bauchner
Howard Bauchner

In a move to keep the Journal of the American Medical Association's publications “user-centric” Editor-in-Chief Howard Bauchner said in a statement that nine publications will get new names in 2013. The rebrand will replace “Archives” in the titles with “JAMA.”

As a result, Archives of Dermatology will be JAMA Dermatology, Archives of Facial Plastic Surgery will be JAMA Facial Plastic Surgery and Archives of Internal Medicine will be JAMA Internal Medicine. JAMA's Neurology, Ophthalmology, Otolaryngology-Head & Neck Surgery, Pediatrics, Psychiatry and Surgery titles will follow suit.

The changeover, which coincides with the first major print redesign of the JAMA network journals in two decades. will be gradual—“Archives” will still appear on the covers for a few months after the new year.

The organization said it will  trim the titles of some journals : Archives of Pediatrics and Adolescent Medicine will surface in 2013 as JAMA Pediatrics and Archives of General Psychiatry will become JAMA Psychiatry.

This would be the second name change for Pediatrics–it was the American Journal of Diseases of Children before becoming an “Archives of” title. Journal editors said in an editorial that new name “reflects the broadening of the bailiwick of the field.” Editors also said adolescents will “remain a central part of who we are as a journal,” even though they've been dropped from the title.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro